| Mar'18 | Mar'17 | Mar'16 | Mar'15 | Mar'14 | Mar'13 | Mar'12 |
|---|---|---|---|---|---|---|
Revenues | ||||||
149,343 | 110,411 | 102,822 | 102,456 | 92,152 | 84,711 | 60,419 |
Direct costs | ||||||
28,933 | 20,723 | 22,425 | 21,070 | 17,088 | 17,167 | 13,761 |
Gross profit | ||||||
120,410 | 89,688 | 80,397 | 81,386 | 75,064 | 67,544 | 46,658 |
Operating (expenses)/income, net | ||||||
Research and development | ||||||
2,028 | 1,506 | 1,390 | 1,598 | 1,572 | 1,362 | 1,209 |
Sales and marketing | ||||||
34,945 | 25,930 | 22,977 | 20,637 | 18,128 | 15,084 | 9,794 |
General and administrative | ||||||
38,819 | 27,595 | 26,357 | 21,242 | 18,056 | 17,396 | 14,243 |
Other operating income from a related party | ||||||
- | 3,823 | - | - | - | - | - |
Total operating expenses, net | ||||||
75,792 | 51,208 | 50,724 | 43,477 | 37,756 | 33,842 | 25,246 |
Operating income | ||||||
44,618 | 38,480 | 29,673 | 37,909 | 37,308 | 33,702 | 21,412 |
Other income/(expenses), net | ||||||
Interest income | ||||||
3,497 | 2,530 | 2,825 | 2,944 | 2,714 | 2,425 | 2,133 |
Interest expense | ||||||
519 | 17,349 | 16,744 | 16,309 | 11,273 | 11,286 | 522 |
Foreign currency exchange gains/(losses) | ||||||
21 | -6 | -151 | -37 | 13 | -158 | -213 |
Dividend income | ||||||
101 | 7 | 7,630 | 378 | 1,594 | 754 | 1,146 |
Impairment loss on available-for-sale equity securities | ||||||
- | 368 | 1,297 | - | - | - | - |
Others | ||||||
673 | 868 | -18 | 139 | 356 | 33 | 117 |
Total other income/(expenses), net | ||||||
3,773 | -14,318 | -7,755 | -12,885 | -6,596 | -8,232 | 2,661 |
Income before income tax | ||||||
48,391 | 24,162 | 21,918 | 25,024 | 30,712 | 25,470 | 24,073 |
Income tax expense | ||||||
9,989 | 5,466 | 7,754 | 7,635 | 9,394 | 6,206 | 1,530 |
Net income | ||||||
38,402 | 18,696 | 14,164 | 17,389 | 21,318 | 19,264 | 22,543 |
Net income attributable to non-controlling interests | ||||||
603 | 363 | 56 | 81 | 100 | 1,158 | 1,586 |
Net income attributable to Global Cord Blood Corporation's shareholders | ||||||
37,799 | 18,333 | 14,108 | 17,308 | 21,218 | 18,106 | 20,957 |
Earnings per share: | ||||||
Basic | ||||||
0.33 | 0.23 | 0.19 | 0.22 | 0.26 | 0.24 | 0.28 |
Diluted | ||||||
0.32 | 0.23 | 0.19 | 0.22 | 0.26 | 0.24 | 0.28 |
Other comprehensive (losses)/income, net of nil income taxes | ||||||
Foreign currency translation adjustments | ||||||
-7,912 | -3,241 | -2,966 | 749 | 1,335 | - | - |
Unrealized holding gains/(losses) in available-for-sale equity securities | ||||||
-4,722 | -5,895 | 5,011 | -4,142 | 9,283 | -1,468 | 7,398 |
- Net effect of foreign currency translation, net of nil tax | ||||||
- | - | - | - | - | 209 | -262 |
Reclassification adjustment for loss included in net income | ||||||
27 | 368 | 1,297 | - | - | - | - |
Total other comprehensive (losses)/income | ||||||
-12,607 | -8,768 | 3,342 | - | - | - | - |
Comprehensive income | ||||||
25,795 | 9,928 | 17,506 | 13,996 | 31,936 | 18,005 | 29,679 |
Comprehensive income attributable to non-controlling interests | ||||||
603 | 363 | 56 | 81 | 100 | 1,155 | 1,633 |
Comprehensive income attributable to Global Cord Blood Corporation's shareholders | ||||||
25,192 | 9,565 | 17,450 | 13,915 | 31,836 | 16,850 | 28,046 |